Co-Diagnostics, Inc. has signed an agreement for CoSara Diagnostics, the Indian joint venture between Co-Dx and Ambalal Sarabhai Enterprises (ASE Group), to significantly expand its commercial and distribution territory across South Asia to now include Bangladesh, Pakistan, Nepal, and Sri Lanka.
The expansion significantly increases CoSara's addressable market across South Asia, bringing the total regional opportunity to an estimated $13 billion based on internal analyses and third-party market data. It also supports CoSara's plans to commercialise the CoSara PCR Pro® point-of-care instrument and tests as well as the SARAGENE® product line across the region, subject to applicable regulatory approvals in each jurisdiction.
As part of this expansion, CoSara is working to establish distribution channels in these newly added markets, including evaluating regulatory pathways, identifying priority customer segments, and engaging regional distribution partners.
Mohal Sarabhai, CEO of CoSara, commented, "Expanding our territory allows us to begin building relationships with regional partners and positions us to support the future commercialization of the point-of-care PCR platform across these markets, increasing access to molecular tests for tuberculosis, HPV, and upper respiratory infections."
Co-Diagnostics CEO Dwight Egan added, "This expansion reflects our broader strategy of establishing regional infrastructure ahead of product commercialization. By building local manufacturing and distribution capabilities in key regions, including the United States, South Asia, and the Middle East and North Africa, we are positioning Co-Dx to support scalable, global deployment of our PCR point-of-care platform and drive long-term growth."
